[TimAlerts] $DYAX deal closeup http://blogs.reuters.com/breakingviews/2015/11/02/shire-pays-up-for-easier-prey-than-baxalta/

[TimAlerts] $DYAX closing weak

[TimAlerts] $DYAX "13:21 EDT - Shire (SHPG) predicts that DX-2930, the rare-disease drug which is the crown jewel of a $5.9B deal for DYAX, will notch $2B in annual worldwide sales. But could its success come at the expense of SHPG's Cinryze and Firazyr drugs, which treat the same hereditary angioedema condition the DYAX compound is targeting? DX-2930 could take sales away from Cinryze, SHPG admits, but it sees overall sales for its HAE franchise increasing from the acquisition as the market is growing amid

[TimAlerts] $DYAX dip

[TimAlerts] $DYAX dropping possible di[p buy

[TimAlerts] $DYAX 1 year breakout pre market

[TimChallenge] Ignore $UNXL and $DYAX?

[TimAlerts] $DYAX up 33% pre market

[TimAlerts] $DYAX unwinding.

[TimChallenge] $MEET DXM EVOK TTPH $DYAX moving